{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:56:56Z","timestamp":1787497016144,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bioorg.2020.104461","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T12:51:25Z","timestamp":1604667085000},"page":"104461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Structure-based design of glycyrrhetinic acid derivatives as potent anti-sepsis agents targeting high-mobility group box-1"],"prefix":"10.1016","volume":"106","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104461_b0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.bioorg.2020.104461_b0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: Analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2020.104461_b0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0883-9441(99)90016-3","article-title":"Il-1ra administration does not improve cardiac function in patients with severe sepsis","volume":"14","author":"Vincent","year":"1999","journal-title":"J. Crit. Care."},{"key":"10.1016\/j.bioorg.2020.104461_b0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CCM.0000000000000043","article-title":"Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-\u0391 Fragment Antibody Azd9773 in adult patients with severe sepsis and\/or septic shock: randomized, double-blind, placebo-controlled phase Iib study","volume":"42","author":"Bernard","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0030","doi-asserted-by":"crossref","unstructured":"S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, J.P. Mira, X. Wittebole, T. Dugernier, D. Perrotin, M. Tidswell, L. Jauregui, K. Krell, J. Pachl, T. Takahashi, C. Peckelsen, E. Cordasco, C.S. Chang, S. Oeyen, N. Aikawa, T. Maruyama, R. Schein, A.C. Kalil, M. Van Nuffelen, M. Lynn, D.P. Rossignol, J. Gogate, M.B. Roberts, J.L. Wheeler, J.L. Vincent, A.S. Group Effect of Eritoran, an Antagonist of Md2-Tlr4, on Mortality in Patients with Severe Sepsis: The Access Randomized Trial, JAMA. 309 (2013) 1154\u20131162.","DOI":"10.1001\/jama.2013.2194"},{"key":"10.1016\/j.bioorg.2020.104461_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","article-title":"Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546c88: effect on survival in patients with septic shock","volume":"32","author":"L\u00f3pez","year":"2004","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0040","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ddmod.2011.09.001","article-title":"When host defense goes awry: modeling sepsis-induced immunosuppression","volume":"9","author":"Hu","year":"2012","journal-title":"Drug Discov. Today Dis. Models."},{"key":"10.1016\/j.bioorg.2020.104461_b0045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"Hmg-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2020.104461_b0050","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00268-005-0369-2","article-title":"Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis","volume":"30","author":"Suda","year":"2006","journal-title":"World J. Surg."},{"key":"10.1016\/j.bioorg.2020.104461_b0055","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/cc5715","article-title":"High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: A prospective study","volume":"11","author":"Ga\u00efni","year":"2007","journal-title":"Crit. Care."},{"key":"10.1016\/j.bioorg.2020.104461_b0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.CCM.0000155991.88802.4D","article-title":"Persistent elevation of high mobility group box-1 Protein (Hmgb1) in patients with severe sepsis and septic shock","volume":"33","author":"Sunden-Cullberg","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/joim.12104","article-title":"Hmgb1 mediates splenomegaly and expansion of splenic Cd11b+ Ly-6c(High) inflammatory monocytes in murine sepsis survivors","volume":"274","author":"Valdes-Ferrer","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0070","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2119\/molmed.2012.00195","article-title":"Hmgb1 mediates cognitive impairment in sepsis survivors","volume":"18","author":"Chavan","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High mobility Group 1 protein (Hmg-1) stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0080","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s12272-012-0901-5","article-title":"Role of high mobility group box 1 in inflammatory disease: focus on sepsis","volume":"35","author":"Bae","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2020.104461_b0085","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41598-017-06205-z","article-title":"Therapeutic targeting of hmgb1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes","volume":"7","author":"Stevens","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2020.104461_b0090","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.20052203","article-title":"Role of Hmgb1 in apoptosis-mediated sepsis lethality","volume":"203","author":"Qin","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0095","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00134-007-0691-2","article-title":"High-mobility Group Box 1 protein plasma concentrations during septic shock","volume":"33","author":"Gibot","year":"2007","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1039\/a902202c","article-title":"The influence of natural products upon drug discovery","volume":"17","author":"Newman","year":"2000","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.bioorg.2020.104461_b0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2020.104461_b0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/np068054v","article-title":"Natural products as sources of new drugs over the last 25 years","volume":"70","author":"Newman","year":"2007","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2020.104461_b0115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/np030096l","article-title":"Natural products as sources of new drugs over the period 1981\u20132002","volume":"66","author":"Newman","year":"2003","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2020.104461_b0120","first-page":"872139","article-title":"Glycyrrhizic acid in the treatment of liver diseases: literature review","volume":"2014","author":"Li","year":"2014","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.bioorg.2020.104461_b0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","article-title":"Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities","volume":"14","author":"Mollica","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2020.104461_b0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/09273948.2010.538121","article-title":"18\u03b2-Glycyrrhetic acid inhibits immune activation triggered by Hmgb1, a Pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis","volume":"19","author":"Cavone","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.bioorg.2020.104461_b0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.6026\/97320630081147","article-title":"Structural Insight into the ligand-receptor interaction between glycyrrhetinic Acid (Ga) and the high-mobility group protein B1 (Hmgb1)-DNA complex","volume":"8","author":"Yamaguchi","year":"2012","journal-title":"Bioinformation."},{"key":"10.1016\/j.bioorg.2020.104461_b0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/jm301248y","article-title":"Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo","volume":"56","author":"Du","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104461_b0145","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bmc.2016.12.045","article-title":"Synthesis of new analogs of Akba and evaluation of their anti-inflammatory activities","volume":"25","author":"Meka","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104461_b0150","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1016\/j.tet.2008.10.035","article-title":"Chemical modifications of natural triterpenes - glycyrrhetinic and boswellic acids: evaluation of their biological activity","volume":"64","author":"Subba Rao","year":"2008","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2020.104461_b0155","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4049\/jimmunol.164.2.966","article-title":"Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors","volume":"164","author":"Cario","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0160","doi-asserted-by":"crossref","first-page":"9719647","DOI":"10.1155\/2017\/9719647","article-title":"Glycyrrhizin protects rats from sepsis by blocking Hmgb1 signaling","volume":"2017","author":"Zhao","year":"2017","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.bioorg.2020.104461_b0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nprot.2008.214","article-title":"Immunodesign of experimental sepsis by Cecal ligation and puncture","volume":"4","author":"Rittirsch","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2020.104461_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"Hmgb1 in health and disease","volume":"40","author":"Kang","year":"2014","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"Hmgb1 Is a therapeutic target for sterile inflammation and infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0898-6568(00)00149-2","article-title":"Lps induction of gene expression in human monocytes","volume":"13","author":"Guha","year":"2001","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2020.104461_b0185","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (Hmgb1): nuclear weapon in the immune arsenal","volume":"5","author":"Lotze","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0190","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.4049\/jimmunol.0900390","article-title":"Hmgb1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of Mapk P38 through receptor for advanced glycation end products","volume":"183","author":"Qin","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nri2035","article-title":"Mapk phosphatases-regulating the immune response","volume":"7","author":"Liu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0200","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0205","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to Nf-Kappab by toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","article-title":"Function and activation of Nf-Kappa B in the immune system","volume":"12","author":"Baeuerle","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2020.104461_b0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10456-008-9093-5","article-title":"Convergence and amplification of toll-like receptor (Tlr) and receptor for advanced glycation end products (rage) signaling pathways via high mobility group B1 (Hmgb1)","volume":"11","author":"van Beijnum","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2020.104461_b0220","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/SHK.0000000000000309","article-title":"Inhibition effect of glycyrrhizin in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from Raw264.7 cells","volume":"43","author":"Wu","year":"2015","journal-title":"Shock."},{"key":"10.1016\/j.bioorg.2020.104461_b0225","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.phrs.2016.06.031","article-title":"Hmgb1 as biomarker and drug target","volume":"111","author":"Venereau","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2020.104461_b0230","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1021\/acs.jmedchem.7b01136","article-title":"High mobility group box-1 (Hmgb1): current wisdom and advancement as a potential drug target","volume":"61","author":"VanPatten","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104461_b0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrd4578","article-title":"Mitigating risk in academic preclinical drug discovery","volume":"14","author":"Dahlin","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bioorg.2020.104461_b0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ecam\/nel093","article-title":"Anti-Inflammatory activity of the methanol extract of moutan cortex in Lps-activated Raw264.7 cells","volume":"4","author":"Chun","year":"2007","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.bioorg.2020.104461_b0245","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jff.2013.01.001","article-title":"Suppressive effect of carotenoid extract of dunaliella salina alga on production of Lps-stimulated pro-inflammatory mediators in Raw264.7 Cells Via Nf-\u039ab and Jnk inactivation","volume":"5","author":"Yang","year":"2013","journal-title":"J. Funct. Foods."},{"key":"10.1016\/j.bioorg.2020.104461_b0250","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/molecules20010625","article-title":"Optimization of Astilbin extraction from the rhizome of smilax Glabra, and evaluation of its anti-inflammatory effect and probable underlying mechanism in lipopolysaccharide-induced Raw264.7 Macrophages","volume":"20","author":"Lu","year":"2015","journal-title":"molecules"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820317594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820317594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:10:13Z","timestamp":1758615013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820317594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"alternative-id":["S0045206820317594"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104461","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design of glycyrrhetinic acid derivatives as potent anti-sepsis agents targeting high-mobility group box-1","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104461"}}